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Introduction
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely 
rare disease that recapitulates some aspects of physiological aging 
(1–5). Accordingly, a detailed understanding of the molecular 
mechanisms underlying HGPS may be useful for the prevention 
of aging or aging-related diseases. In fact, it has been shown that 
progerin, a gene product of HGPS cells derived from an aberrant 
splicing process (6, 7), is also detected in non-HGPS aged cells (8, 
9). Progerin expression induces several changes in cellular mor-
phology, such as nuclear membrane blebs and a reduction of nuc-
leoplasmic lamin A (10, 11), whereas progerin downregulation res-
cues nuclear deformation (10, 12), indicating that progerin gain of 
function is a causal factor for HGPS. It has also been reported that 
progerin accumulates in several human cancer cells (13, 14) and 
induces nuclear deformation (9–11). Notably, expression levels of 
progerin and lamins A and C (lamin A/C) are significantly reduced 
in induced pluripotent stem cells (iPSCs) derived from patients 
with HGPS (15, 16). Likewise, cellular senescence markers, includ-
ing nuclear deformation, histon e H3 trimethyl Lys9 (H3K9Me3) 
and senescence-associated β-gal (SA–β-gal), are also decreased 
in these cells. By contrast, differentiated HGPS cells re-express 
senescence markers following progerin expression (15).
Despite several reports dealing with the role of this protein 
in cell-cycle regulation (11, 17, 18) and senescence (12, 19), how 
progerin induces various cellular defects and premature aging 
remains to be revealed. Remarkably, proteomic studies and 
2-hybrid approaches have identified lamin A/C as a progerin-bind-
ing protein (20, 21). On this basis, we hypothesized that the inter-
action of progerin with lamin A/C contributes to the development 
of the senescence phenotype of HGPS and aged cells.
Results
Direct interaction between progerin and lamin A/C but not lamin 
B. To investigate our hypothesis, we performed a binding assay 
and found that C-terminal progerin and lamin A associated with 
lamins A and C but not with lamin B1 (Figure 1A and Supple-
mental Figure 1A; supplemental material available online with 
this article; doi:10.1172/JCI84164DS1). In addition, the binding 
affinity between progerin and lamin A/C was stronger than that 
between lamin A/C and lamin A/C (Figure 1B and Supplemental 
Figure 1B). To dissect the progerin domain involved in lamin A/C 
binding, we performed a glutathione-S-transferase pull-down 
(GST pull-down) assay using a His-tagged lamin A N-terminal 
region (LMNA-N; aa residues 1-300) and a lamin A middle region 
(LMNA-M; aa residues 301-564) with bead-coupled GST–C-ter-
minal fragments of lamin A (GST-LMNA) or progerin (GST- 
progerin). We found that the middle region of lamin A was respon-
sible for progerin binding (Figure 1, C and D). We could confirm 
the direct interaction of both proteins through Far Western blot 
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cals, particularly JH4, because JH1 and JH13, despite their similar 
effects, show very low solubility. We first confirmed their inhibito-
ry effect of the JH chemicals on the binding between progerin and 
lamin A through in vitro binding assays (Supplemental Figure 2E). 
Indeed, less than 1 μM of JH4 (IC50 = 0.65 μM) could block 50% of 
the interaction between progerin and lamin A without disruption 
of lamin A self-association (Supplemental Figure 2E).
The effect of progerin–lamin A–binding inhibitors in HGPS model 
cells. To confirm the inhibitory effect of JH chemicals on binding 
between progerin and lamin A, we performed the GST  pull-down 
assay and observed that JH4 blocked the interaction of GST–lamin 
A with GFP-progerin, but not with GFP–lamin A, in a GST pull-
down assay using cell lysates (Figure 2A and Supplemental Figure 
3A). However, the farnesyltransferase inhibitor FTI-277, known to 
ameliorate nuclear deformation (23, 24), did not show an obvious 
effect on progerin–lamin A binding (Figure 2A and Supplemental 
Figure 3B). Next, we checked their in vivo effect in progerin and 
GFP–lamin A–transfected HEK293 cells through IP assays with 
an anti-GFP Ab. The binding between progerin and lamin A was 
markedly reduced  by the JH chemicals, while the binding between 
lamin A and lamin B was not affected by these compounds (Figure 
2B). Additionally, a reduction of p16INK4A expression was detected 
in response to treatment with the JH chemicals (Figure 2B). We 
also observed the different localization of progerin from that of 
lamin A upon JH4 treatment (Figure 2C and Supplemental Figure 
3C). Moreover, all these JH compounds, and in particular JH4, 
blocked nuclear deformation (Supplemental Figure 4, A and B). 
These results indicate that JH4 (and JH13 to some extent) blocked 
the interaction between progerin and lamin A and alleviated pro-
gerin-induced nuclear deformation. However, JH4 did not show 
any significant effect on the localization pattern of other lami-
nopathy-related lamin A mutants (2) such as nuclear speckles of 
D192G (Supplemental Figure 4C). This result also supports the 
idea that JH4 possesses selective activity on progerin. Next, we 
examined the effect of JH chemicals on HGPS cells. Consistent 
with the above results, JH chemicals, in particular JH4, blocked 
the interaction between progerin and lamin A in these progeroid 
cells (Figure 2D and Supplemental Figure 4D), without alteration 
of progerin mRNA expression (Supplemental Figure 4E). In addi-
tion, JH chemicals, and especially JH4, ameliorated the frequency 
of nuclear deformation of HGPS cells (Figure 2, E and F, and Sup-
plemental Figure 4, F and G).
Specific interaction of JH4 and progerin. To determine the direct 
target of JH chemicals, we monitored their effect on the previously 
observed progerin-p14ARF binding (14). In this assay, we found that 
JH chemicals blocked the interaction between progerin and p14ARF 
(Supplemental Figure 5A), but not between p53 and p14ARF (ref. 25 
and Supplemental Figure 5B). In addition, JH4 did not block the 
interaction between progerin and MEL18/BMI1 that is achieved 
by the middle region of lamin A (ref. 26 and Supplemental Figure 
5, C–E). Considering these facts, the C-terminal region of progerin 
may be the direct target of JH4 (Supplemental Figure 5F). To verify 
this hypothesis, we generated biotinylated JH4 (Supplemental Fig-
ure 5G; B33: precursor for biotinylation; 07: biotinylated JH4; 08: 
biotin plus linker). Modified chemicals showed inhibitory activity 
similar to that of JH4 on binding between lamin A and progerin 
(Supplemental Figure 5H) as well as on nuclear deformation (Fig-
analysis (Supplemental Figure 1C). Considering that progerin can 
strongly interact with LMNC (which corresponds to aa 1-572 of 
LMNA), we excluded the possibility that the C-terminal extension 
region of LMNA is a target of progerin. By ELISAs with an immobi-
lized LMNA-M domain and the GST-fused recombinant lamin A or 
progerin, we could estimate that progerin–lamin A binding affinity 
is more than 2-fold stronger than that of lamin A–lamin A binding 
(Figure 1E). Considering that lamins A and C form intermediate fil-
aments by head-to-tail binding and bundle through the C-terminal 
and middle regions (22), progerin may induce a stronger or tighter 
but irregular bundle formation than does lamin A or C alone. This 
hypothesis was consistent with the HGPS cell phenotype, in which 
lamins A and C formed an irregular fiber arrangement (Supple-
mental Figure 1, D and E). Indeed, progerin alone did not induce 
nuclear deformation in lamin A/C-deficient neuron or embryonic 
neuron cells, whereas cotransfection with lamin A could induce it 
(Figure 1, F and G, and Supplemental Figure 1, F and G), despite 
low expression of progerin in N2A cells (Supplemental Figure 1G). 
These results indicated that nuclear lamina alteration can derive 
from the strong binding of progerin to lamins A and C.
Screening of specific binding inhibitor of progerin–lamin A bind-
ing. The above findings prompted us to search for putative proger-
in/lamin A–binding inhibitors by using an ELISA-based screening 
system. In brief, progerin, immobilized in 96-well plates, was 
incubated sequentially with a chemical library and His–lamin 
A (Supplemental Figure 2, A and B). This screening identified 5 
chemicals that blocked this interaction (JH1, JH4, JH13, LG-02, 
and KEK-2-24, Supplemental Figure 2C). Because KEK-2-24 is a 
mixture of compounds from Panax ginseng and LG-02 requires 
complicated synthetic steps, we excluded them from further 
study. A detailed synthetic pathway for the selected chemicals is 
described in the Chemical Synthesis section of the Supplemental 
Methods. Interestingly, in spite of the blind screening, the selected 
chemicals were structurally similar (Supplemental Figure 2C) and 
showed very low cytotoxicity (Supplemental Figure 2D). There-
fore, we decided to further investigate the activity of JH chemi-
Figure 1. Identification of a lamin A–progerin–binding inhibitor. (A) 
Interaction of progerin and LMNA A/C but not lamin B. GST pull-down 
assay using lysates from HEK293 cells transfected with lamins A, B, C and 
progerin after incubation with the C-terminal 100-aa sequence of lamin 
A (564-664 aa; GST-LMNA) or 50-aa sequence of progerin (564-614 aa; 
GST-progerin). (B) Strong interaction between lamin A and progerin. Lamin 
A–progerin interaction was detected after a 1-hour incubation. However, 
progerin did not show evidence of self-association. Rx, treatment. (C) 
Direct interaction between lamin A and progerin. In vitro–binding assay 
using His-tagged N-terminal (1-300 aa; LMNA-N) and the middle region 
(LMNA-M) of lamin A after incubation with GST-LMNA or GST-progerin. 
Associated proteins were analyzed by Western blotting. N, LMNA-N; M, 
LMNA-M. (D) Scheme of the interaction between lamin A and progerin. (E) 
ELISA results. His-tagged LMNA-M was fixed in a 96-well plate and incu-
bated with GST-LMNA or GST-progerin. Photograph of the 96-well plate 
(inset) and ELISA value. (F and G) Progerin did not induce nuclear deforma-
tion in neuron or embryonic neuron cells. Transfection of GFP-progerin or 
lamin A alone into the neuroblastoma cell line SH-SY-5Y (F) and the mouse 
neuroembryonic cell line N2A did not induce nuclear deformation. Howev-
er, cotransfection could induce it. Cells were transfected with the indicated 
vectors for 24 hours. For visualization of the nuclear membrane, cells were 
stained with emerin (red) and DAPI for DNA (blue). Scale bar: 10 μm.
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JH4 reduces progerin expression in immunofluorescence staining 
(Figure 2C). To confirm the antisenescence effect, we examined 
the expression of H3K9Me3 and DNA-dependent protein kinase 
(DNA-PK), whose reduced levels have been proposed as markers 
of senescence (9, 15). Interestingly, JH4 and JH13 increased the 
expression of H3K9Me3 (Figure 4G and Supplemental Figure 6, 
E and F) and the DNA-PK catalytic subunit (DNA-PKcs) in HGPS 
cells (Supplemental Figure 6, G and H).
Antisenescence effect of JH chemicals on normal aged human 
fibroblasts. Since progerin-induced nuclear deformation is also 
observed in aged cells, we hypothesized that the JH chemicals 
may also decelerate the normal aging process. To address this, we 
checked the expression of progerin in normal fibroblasts obtained 
from an 81-year-old donor (N81). These cells expressed progerin 
at the transcriptional level (Supplemental Figure 7A) and showed 
abnormal nuclear morphology, similar to what was observed in 
HGPS cells (Supplemental Figure 7B; arrowheads). These results, 
together with previous reports showing that progerin accumulates 
in aged cells and causes nuclear deformation (8, 9), prompted us 
to hypothesize that the JH chemicals could prevent senescence of 
aged cells. Indeed, the nuclear morphology of the 81-year-old cells 
was clearly improved by JH chemicals and FTI-277 (Figure 5A and 
Supplemental Figure 7C). Moreover, the slow proliferation of nor-
mal 81-year-old fibroblasts was completely rescued by JH4 (Figure 
5B). To check the possible long-term toxicity of this treatment, we 
incubated fibroblasts from young, old, and HGPS human tissues 
with JH4 for 10 days and found that this compound could pro-
mote cell growth and colony formation without obvious toxici-
ty (Supplemental Figure 7, D and E). In SA–β-gal assays, we also 
observed that JH4 could block cellular senescence (Figure 5C). 
Consistently, expression of Ki-67 (30), a cell proliferation mark-
er, was increased after JH4 treatment (Supplemental Figure 7F). 
Additionally, increased H3K9Me3 (Figure 5D) and reduced DcR2 
and p16INK4A levels were detected by JH4 treatment in normal aged 
fibroblasts (Figure 5E). Thus, we next checked the effect of JH4 on 
oncogene-induced or growth factor–induced senescence (31, 32). 
Senescence induced by IGF-1 treatment or transfection of onco-
genic Ras into WI-38 (normal foreskin fibroblast) was not blocked 
by JH4 (Supplemental Figure 7, G and H), because oncogene- 
induced senescence did not induce progerin (Supplemental Figure 
7I), nor was induction of p16 blocked by JH4 treatment (Supple-
mental Figure 7I). In addition, JH4 did not promote cell viability in 
human cancer cell lines, despite a 72-hour treatment (Supplemen-
tal Figure 8A), suggesting that the antisenescence effects of JH4 
do not result in the promotion of cancer progression. Instead, JH4 
could ameliorate the nuclear deformation in renal cell carcinoma 
induced by progerin expression (Supplemental Figure 8B), with 
slight growth suppression at a high concentration (Supplemental 
Figure 8C). These results suggest that JH chemicals, in particular 
JH4, selectively block progerin-mediated senescence, without 
growth promotion of progerin-negative cells.
Restoration of aging-related gene expression profile by JH4 treat-
ment. To gain further insight into the biological effects of JH4, 
we investigated its impact on gene expression profiles. For this 
purpose, we hybridized oligonucleotide microarrays with RNA 
samples from HGPS-1, JH4-treated HGPS, young (9-year-old; 
N9), and old (81-year-old; N81) fibroblasts. Among 14,400 genes 
ure 3A and Supplemental Figure 5I). Then, we checked the loca-
tion of biotinylated JH4 using avidin-HRP and found that JH4 was 
located in the nuclear membrane of progerin-transfected cells 
(Figure 3B) and HGPS, but not in the nuclear membrane of nor-
mal cells (Figure 3C and Supplemental Figure 5J). In addition, a 
biotin-avidin bead pull-down assay showed specific interaction of 
JH4-biotin with progerin (Figure 3D) but not with lamin A, lamin 
B, p53 , or emerin (Figure 3, D and E), indicating that progerin is 
the primary and direct target of JH4.
Antisenescence effect of JH chemicals on HGPS cells. We next 
examined the effect of JH chemicals on senescence. Since an 
important feature of senescence is an irreversible cell proliferation 
arrest (27), we checked the effect of JH chemicals on cell prolif-
eration and found that these compounds (and in particular JH4) 
promoted the proliferation of HGPS cells (Figure 4A). In addition, 
JH4 promoted the proliferation of other kinds of HGPS cells (Fig-
ure 4B). Indeed, JH4 could induce the expression of Ki-67, a cell 
proliferation marker, in HGPS cells (Figure 4C). SA–β-gal staining, 
a standard senescence assay (28, 29), also showed antisenescent 
activity of JH4 in HGPS cells, which was similar to that induced 
by FTI treatment (Figure 4D and Supplemental Figure 6, A and 
B). Decoy Receptor 2 (DcR2) expression (29) was also reduced in 
HGPS cells at both the RNA and protein levels after treatment of 
these cells with JH chemicals (Supplemental Figure 6, C and D). 
Since progerin levels were reduced by JH4 (Supplemental Figure 
6D) without a reduction of the mRNA levels (Supplemental Figure 
4F), we speculated that progerin, dissociated from lamin A, may 
lose its stability. Indeed, JH4 could reduce the half-life of proger-
in (Figure 4E), which was restored by incubation with the prote-
asome inhibitor N-acetyl-leucinyl-leucinyl-norleucinal (ALLN) 
(Figure 4F). This result is consistent with our previous finding that 
Figure 2. Ameliorating effect of JH chemicals on nuclear deformation. 
(A) Specific effect of JH chemicals on the binding of lamin A–progerin but 
not on that of lamin A–lamin A. GST pull-down assay using lysates from 
HEK293 cells transfected with GFP-LMNA after incubation with GST- 
LMNA or GST-progerin under treatment with the indicated chemicals. (B) 
Dissociation of lamin A and progerin by JH4 in human cells. Dissociation 
of progerin from lamin A/C was confirmed by IP in HEK293 cells. For this, 
GFP-progerin–transfected HEK293 cells were incubated with the indicated 
chemicals (5 μM) for 24 hours. A reduction of p16INK4A was also detected in 
whole-cell lysate. Actin was used as a loading control. SUP, supernatent. 
(C) JH4 blocked the colocalization of lamin A and progerin. For this, HEK293 
cells were cotransfected with GFP-LMNA and nontagged progerin (NT 
progerin) for 24 hours and incubated with JH4 for an additional 24 hours. 
JH4 could abolish the colocalization of lamin A and progerin (red) in the 
nuclear membrane or in nuclear speckles. DAPI was used for DNA staining. 
Scale bar: 10 μm. (D) JH4 blocks the interaction of lamin A and progerin in 
HGPS cells. Treatment with 5 μM JH4, but not FTI-277, for 24 hours blocked 
the interaction of lamin A and progerin in HGPS cells. Cell lysates were 
immunoprecipitated with a lamin A–specific Ab (H-102, sc-20680) and 
immunoblotted with a progerin-specific Ab. Normal cells (9 yr; N9) were 
used as a negative control for progerin. (E) Effect of JH chemicals on nucle-
ar deformation of HGPS cells. Three kinds of HGPS cells were incubated 
with the indicated chemicals for 24 hours and fixed for lamin A/C immu-
nofluorescence analysis (green). The same effect was observed in other 
HGPS cells (Supplemental Figure 4F). Scale bars: 10 μm. (F) Quantification 
of nuclear abnormalities in HGPS cells. JH chemicals, in particular JH4, 
ameliorated nuclear deformation of HGPS cells. P values were determined 
by Student’s t test. PPT, protein pellet.
Downloaded from http://www.jci.org on March 20, 2018.   https://doi.org/10.1172/JCI84164
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
3 8 8 4 jci.org   Volume 126   Number 10   October 2016
present in the array, 1,921 showed differential expression (cutoff of 
2-fold; Figure 5A and Supplemental Figure 9A). After elimination 
of nonsignificant changes resulting from the comparison between 
HGPS and young cells (Supplemental Figure 9A and Supplemen-
tal Table 1), we classified differential genes in an HGPS unique 
gene set (HUG), an aging unique gene set (AUG), and an HGPS/
aging-related gene set (HARG) (Figure 6A, Supplemental Figure 
9B, and Supplemental Tables 2 and 3). Next, we defined a set of 
genes whose expression is restored by JH4 treatment (HARG/
JR) (298 genes; Supplemental Figure 9B and Supplemental Table 
Figure 3. Progerin is a direct target of the JH4 chemical. (A) Effect of biotinylated JH4 on nuclear deformation of HGPS cells. Cells were incubated with the 
indicated chemicals for 24 hours and fixed for lamin A/C immunofluorescence analysis (green). Scale bars: 10 μm. (B) Localization of JH4 in progerin-trans-
fected HEK293 cells. JH4-biotin (07), but not biotin alone (08), was stained in the nuclear membrane by streptavidin-HRP in progerin-transfected cells. 
Prg, progerin. Original magnification, ×200. (C) JH4 locates in the nuclear membrane. After treatment with biotinylated JH4 for 48 hours, cells were fixed 
and stained with streptavidin-FITC. Green signal was detected only in JH4-treated HGPS. Scale bars: 10 μm. (D) Specific interaction of JH4 and progerin. 
Streptavidin-biotin–binding assay using lysates from HGPS cells incubated with biotinylated JH4 or biotin. After incubation with streptavidin-coated mag-
netic beads, the biotinylated JH4 with the protein complex was isolated. (E) Direct and specific interaction between JH4-biotin and progerin. Cells incubat-
ed with the indicated chemicals were lysed with RIPA and incubated with streptavidin-coated beads. Material precipitated by the biotin-streptavidin-bead 
complex was analyzed by Western blot analysis. GFP-progerin was precipitated by the biotin-streptavidin complex in JH4-biotin–treated cells. However, 
other nuclear membrane proteins such as lamin B (LMNB), emerin and GFP–lamin A, and p53 were not associated with JH4-biotin. WCL, whole-cell lysate.
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4). To verify these transcriptomic results, we confirmed that the 
expression of several genes such as IL33, breast cancer 1 (BRCA1), 
bloom syndrome RecQ-like helicase (BLM), RAD51 recombinase 
(RAD51), IL6, IL8, and tumor necrosis factor superfamily member 
18 (TNFSF18) was altered at both the protein and mRNA levels after 
JH4 treatment (Figure 6, B and C). By contrast, farnesyltransferase 
inhibitor (FTI) treatment did not revert the expression changes of 
the HARG/JR genes (Supplemental Figure 9C), indicating that the 
Figure 4. Antisenescence effect of the JH chemicals on HGPS cells. (A) JH chemical overcame the growth suppression of HGPS cells. After seeding at  
1 × 104 cells per well, cell proliferation was determined by cell counting every 48 hours for 6 days. The experiment was performed in triplicate. *P = 0.01,  
**P = 0.016.  P values were determined by Student’s t test. (B) Cell proliferation assay of normal cells obtained from a 9-year-old person (N9) under the 
same condition as above. JH4 could induce proliferation of normal cells, particularly at late time points (between 4 and 6 days). (C) Induction of Ki-67 by 
JH4 in HGPS cells. Three types of HGPS cells were incubated with JH4 for 48 hours and stained with Ki-67 Ab (red). Scale bars: 10 μm. (D) JH chemicals sup-
pressed SA–β-gal expression in HGPS cells. SA–β-gal assay of HGPS cells incubated with JH chemicals (5 μM, for 48 hours). The same result was obtained 
for other HGPS cells (Supplemental Figure 7A). Original magnification, ×40. (E) JH4 suppressed the half-life of progerin. Pulse-chase analysis using the de 
novo synthesis inhibitor cycloheximide (CHX) showed a rapid reduction of progerin by treatment with JH4. Cells, transfected with GFP-LMNA or GFP-pro-
gerin vectors, were incubated with 10 μM CHX for the indicated durations, with or without 5 μM JH4. (F) The proteasome inhibitor ALLN blocked progerin 
downregulation by JH4. (G) JH chemicals induced H3K9Me3 in HGPS cells. Cells, incubated with the indicated chemicals (5 μM) for 48 hours, were fixed with 
100% Me-OH and stained with anti-H3K9Me9 Ab (green). DAPI was used for DNA staining (blue). Scale bars: 10 μm. Con, control.
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blasts (N81; N72, 72-year-old; and N94, 94-year-old) and HGPS-2 
cells  compared with the levels detected in fibroblasts from N9 (Sup-
plemental Figure 9D). In contrast, IL6 and IL8 were overexpressed 
in these cells (Supplemental Figure 9D). This result suggested that 
alternation of these expression levels would result from aging. To 
investigate the biological significance of these transcriptional alter 
effects of JH4 and FTI are markedly different. Since the alterna-
tion of gene expression is due to a different genetic background but 
not to aging, we examined the expression of several genes induced 
or suppressed in aged fibroblasts and HGPS cells in other kinds of 
human aged fibroblasts and different HGPS cells. Expression levels 
of IL33, RAD51, and BRCA1 were reduced in 3 kinds of aged fibro-
Figure 5. Antisenescence effect of JH chemicals on normal aged cells. (A) Nuclear deformation of aged fibroblasts was ameliorated by JH4. Normal cells 
obtained from 9-year-old (N9) and 81-year-old (N81) subjects were incubated with JH4 (5 μM) for 48 hours and stained with anti–lamin A/C Ab (green). 
DAPI was used for DNA staining. Scale bars: 10 μm. (B) JH4 could induce cell proliferation in aged fibroblasts. After seeding 7.5 × 104 cells per well, cells 
were maintained for a maximum of 6 days with the indicated JH chemicals (5 μM). Cell numbers were calculated every 48 hours. The slow proliferation of 
cells from N81 compared with that of cells from N9 (Figure 4B) was completely rescued by JH4 treatment. *P = 0.013. The P value was determined by Stu-
dent’s t test for analysis of statistical significance between 2 groups. (C) JH4 suppressed senescence of N81 fibroblasts. An SA–β-gal assay was performed 
on cells from N81 after treatment with the indicated chemicals (5 μM) for 48 hours. Original magnification, ×40. (D) JH4 induced H3K9Me3 expression in 
normal aged cells. Immunofluorescence for H3K9Me3 (green) was performed in N9 and N81 cells under treatment with the indicated chemicals (5 μM) for 
48 hours. Scale bars: 10 μm. (E) JH4 suppressed DCR2 and p16INK4A in normal human cells. Reverse transcriptase-PCR (RT-PCR) analysis of the indicated 
genes was performed in normal cell lines (N9, N29, and N81) after treatment with JH4 for 48 hours.
Downloaded from http://www.jci.org on March 20, 2018.   https://doi.org/10.1172/JCI84164
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3 8 8 7jci.org   Volume 126   Number 10   October 2016
Figure 6. Aging-related gene expression is 
recovered by JH4 treatment. (A) Heatmap of 
gene expression profiles showing a difference 
of at least 2-fold in both cell lines. Colors 
represent values normalized to the range of 
intensity for each gene in all conditions.  (B) 
Reduced expression of IL33, BRCA1, BLM, 
and RAD51 in HGPS cells was reverted by JH4. 
Conversely, IL6, IL8, and TNFSF18 overexpres-
sion was suppressed by JH4 treatment. (C) JH4 
could alter HGPS-specific gene expression. 
RAD51, BRCA1, cyclin B1, and CDC25C protein 
expression levels were increased by treatment 
with JH4. (D) Network analysis using cBiopor-
tal. Genes in the HARG/JH group were clustered 
into chromosome separation, DNA replication, 
DNA repair, and cell-cycle groups. (E) JH4 
overcame progerin-induced cell-cycle arrest. 
Cell-cycle arrest at the G2/M phase by progerin 
transfection was released by JH4 treatment  
(5 μM, for 24 hours).
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lamin A aggregation in nocodazol- or Taxol-treated cells was 
abolished by JH4, but not by FTI-277 (Supplemental Figure 
10, B and C). To gain further insight into this observation, we 
analyzed the localization of progerin in nocodazol- or Taxol- 
treated cells. Cytoplasmic aggregates in nocodazol- or Taxol- 
treated cells were undetectable upon JH4 treatment, but not 
after incubation with FTI-277 (Supplemental Figure 11A). Given 
the role of the ER in nuclear lamina remodeling during the G2/M 
phase (23), we investigated the subcellular localization of lamin 
A and an ER-specific marker (35) in JH4-treated cells and found 
that aggregates of lamin A in the ER disappeared after JH4 treat-
ment (Supplemental Figure 11B). Next, we checked the location 
of progerin after arrest at the M phase by Taxol treatment and 
found that JH4 also blocked ER-associated progerin during the M 
phase (Supplemental Figure 11C). To confirm whether M-phase 
aggregates contain lamin A–progerin complexes, we costained 
lamin A–GFP and progerin in Taxol-treated cells. Colocalized 
lamin A and progerin in the non-nuclear region was abrogated by 
JH4 (Supplemental Figure 11D). This result indicates that proger-
in disrupts lamin A dissemination and reduction during the G2/M 
phase by direct binding to this nuclear envelope protein. Indeed, 
it has been recently reported that HGPS cells show downregu-
lated and defective poly(ADP-ribose) polymerase 1 (PARP1) in 
G2/M-phase progression (36).
Therapeutic effect of JH4 on the HGPS mouse model. To evaluate 
the therapeutic potential of JH4 in vivo, we injected i.p. 10 mg/kg 
of this compound twice per week into 4-week-old LmnaG609G/G609G 
HGPS mice, a suitable murine model of human HGPS (37). After 4 
weeks of treatment, we observed a significant increase in BW (Fig-
ure 7, A and B), which continuously increased out to 12 weeks (Sup-
plemental Figure 12A). By contrast, vehicle-treated mice showed 
a significant decrease in BW after the eighth week (Figure 7B and 
Supplemental Figure 12A). At 11 to 12 weeks, the difference in BW 
between vehicle- and JH4-treated mice reached 4 g (about 25%; 
Supplemental Figure 12A). In addition, injection of JH4 increased 
grab strength (Figure 7C) and suppressed hair loss at week 15 
(Supplemental Figure 12B). Consistently with the increase in BW, 
the size of different organs was increased by JH4 administration 
(Figure 7D). Moreover, organ size recovery was fully dependent 
on the number of injections given (Figure 7E and Supplemental 
Figure 13), such that 5 weeks after the start of treatment (10 injec-
tions), thymus and spleen volumes were enlarged by approximate-
ly 2-fold when compared with tissues from vehicle-treated mice 
(Figure 7E). Since progerin induces a cell-cycle arrest that seems to 
be critical for growth retardation (17, 18, 37), we also analyzed cell- 
cycle dynamics and found that it was also promoted by JH4 (Fig-
ure 7F and Supplemental Figure 12C) in a number of injection- 
dependent ways (Supplemental Figure 13, A7 and B7). Histologi-
cal analysis revealed that JH4 increased skin thickness, reduced 
kidney destruction, and alleviated nuclear deformation (Figure 
7G and Supplemental Figure 12D). To obtain more detailed evi-
dence, we measured the cell density and frequency of deformed 
nuclei in heart (Figure 7, H and I), liver (Supplemental Figure 12E), 
lung (Supplemental Figure 12F), and kidney (Supplemental Figure 
12G). In all examined tissues, JH4 treatment increased cell den-
sity and reduced the number of deformed nuclei. For example, 
the reduction in cell numbers in the same region or in tubes and 
ations, we analyzed the altered gene networks using cBioportal 
(33, 34) and found that many genes in the HARG/JR group were 
clustered in 4 functional categories: chromosome segregation, cell 
cycle, DNA repair, and DNA replication (Figure 6D). For example, 
genes encoding BUB1 (budding uninhibited by benzimidazoles 
1), shugoshin-like 1 (SGOL1), centromere protein (CENP) family 
proteins (chromosome segregation), cyclin B2, cyclin-dependent 
kinase 1 (CDK1) (cell cycle), BRCA1, BRCA2, RAD51 (DNA repair), 
and minichromosome maintenance protein complex (MCM) fam-
ily proteins were listed in this group (Supplemental Figure 9, E and 
F). On the basis of gene function, we grouped all JH4-responding 
genes into 18 categories (Supplemental Figure 9G). Consistent with 
what we observed with the protein network, the majority of HARG/
JR was clustered in the cell cycle, DNA replication, chromosome 
regulation, and DNA repair. In agreement with these findings, JH4 
could overcome the progerin-induced cell-cycle arrest, in particu-
lar at the G2/M phase (Figure 6E).
JH4 blocks progerin-induced lamin A aggregation in ER during 
the G2/M phase. Because many of the JH4-responsive genes 
shown in Supplemental Table 4 and Figure 4B are involved in 
cell-cycle and chromosome regulation and progerin induces 
cell-cycle arrest at the G2/M checkpoint (Figure 6E), we exam-
ined the effect of JH4 on the behavior of lamin A at the G2/M 
phase. Dispersal of lamin A upon treatment with Taxol (pacli-
taxel) was observed in young, but not aged, cells. Rather, lamin 
A surrounded chromosomal or nuclear DNA (Supplemental 
Figure 10A, white arrows). However, treatment with JH4 could 
promote lamin A elimination in aged cells (Supplemental Figure 
10A, yellow arrows). We also observed that progerin-induced 
Figure 7. JH4 prevents progeroid phenotypes in LmnaG609G/G609G mice. (A) 
Representative photographs of 8-week-old LmnaG609G/G609G mice (female, 
left; male, right) treated with JH4 (10 mg/kg twice per week). Mice were 
injected 8 times (from 4 weeks of age). (B) Increase in BW of LmnaG609G/G609G  
mice following JH4 injection. P values were determined by Student’s t test. 
(C) Increase in muscle strength following JH4 injection. Grip strength was 
measured for LmnaG609G/G609G, Lmna+/G609G, Lmna+/+ male mice by pulling 
the spring balance after treatment with JH4 or vehicle alone. P value was 
determined by Student’s t test. (D) Growth morphology of thymus and 
spleen from 9-week-old LmnaG609G/G609G mice treated with vehicle or JH4. An 
obvious enlargement of both organs after JH4 treatment was observed. (E) 
JH4 injection time–dependent organ size increase. Compared with vehicle- 
injected mice, the size of several organs was gradually increased by treat-
ment time. Numbers above each bar indicate the fold increase at each time 
point (see also Supplemental Figure 14). (F) JH4 injection promoted the 
cell cycle of splenocytes obtained from 7-week-old mice (injected 6 times). 
Cell-cycle promotion was observed in JH4-treated cells. (G) Rescue of cell 
and tissue defects. Foot pad skin was thickened and dermal connective 
tissue was enriched in JH4-treated animals (upper panels). Kidney tissue 
was well organized after JH4 treatment. Tissues were obtained from 
18-week-old (vehicle) and 22-week-old (JH4) mice. Scale bar: 80 μm, original 
magnification ×100. (H) Increase in cell density and reduction of deformed 
cell nuclei in JH4-treated heart tissue obtained from the same mice above. 
On the basis of the histology, nuclear morphology (right) and cell density 
(left) were counted for 3 different mice and 5 different regions per mouse by 
3 researchers. P values were determined by Student’s t test. (I) Represen-
tative images of heart muscle. Arrows indicate deformed nuclei. Scale bar: 
10 μm. (J) JH4 suppressed progerin and induced RAD51 and phosphorylated 
CDC2 (p-CDC2). Western blot analysis was performed using extracts from 
liver and kidney tissue obtained from 18-week-old sibling mice.
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injection. As shown in Figure 8E, the lifespan of JH4-treated pro-
geroid mice was extended by more than 4 weeks compared with 
that of vehicle-treated mice. Although JH4 treatment did not ful-
ly overcome the short lifespan of these animals, considering the 
low concentration (10 mg/kg) and frequency (2 times/week) of 
administration, it appears to have a promising effect. In fact, JH4 
also significantly extended the lifespan of Lmna+/G609G heterozy-
gous mice (Figure 8F). Since biological effect of JH4 was dose- 
dependent, we injected 20 mg/kg JH4 into LmnaG609G/G609G pro-
geroid mice. From this experiment, we found that 20 mg/kg JH4 
could extend lifespan by as much as 26 weeks (Figure 8G). These 
results suggest that if JH4 can be retained at a higher concentration, 
lifespan could be more dramatically extended and that JH4 would 
be a strong therapeutic drug candidate for the treatment of HGPS.
Discussion
The aging process is complicated, and a full understanding of the 
molecular mechanisms controlling it is not likely to be realized in 
the near future. However, some basic clues are known from study-
ing human progeria syndromes such as HGPS (39–41). Although 
HGPS is caused by progerin, a product of a point mutation in the 
LMNA gene, progerin is also expressed in normal aged cells as well 
as in cancers (14). Thus, understanding the pathological function 
of progerin is useful for the development of a therapeutic strategy 
to treat HGPS as well as for the prevention of aging.
In fact, over the past decade, the farnesylation of progerin 
has been targeted for drug development to treat HGPS. (24, 42). 
Because the farnesylated domain of progerin rigidly anchors it to 
the nuclear membrane, it may induce nuclear deformation. Block-
ing farnesylation by FTIs in HGPS cells restores nuclear morphol-
ogy, cell proliferation, and heterochromatin organization. More-
over, treatment with FTIs in HGPS-like mouse models improves 
lifespan, growth, and BW and relieves premature aging symptoms 
such as bone defects (23). In particular, FTIs can extend the lifes-
pan of Zmpste24–/– mice (24). However, a clinical trial of FTI did 
not produce promising results (43), indicating that other targets 
should be explored.
In this study, we found that the most important target of 
progerin is lamin A/C. Indeed, progerin shows strong binding 
affinity for lamin A/C but not lamin B (Figure 1E). On this basis, 
we found new chemicals that can block the interaction between 
progerin and lamin A/C through direct interaction with proger-
in (Figure 2B and Figure 3E). Since the chemical JH4 can bind 
selectively to progerin, there would be very minimal, nonspecif-
ic side effects. In our study, JH4 did not show an effect on the 
progerin-independent progeria model (Zmpste24–/– mice; Sup-
plemental Figure 14C) or on mouse and monkey cell lines (data 
not shown). These results indicate that JH4 has potential use as a 
progerin-inhibitory drug.
Although JH4 did not fully overcome the short lifespan of 
the LmnaG609G/G609G mouse model, given the low dose and infre-
quent injections of the compound, an optimized treatment strat-
egy using JH4 could offer an effective therapy. Indeed, the same 
scheduled injection produced more obvious effects in Lmna+/G609G 
mice (Figure 8), and JH4 appeared to be excreted within 24 hours.
In summary, in this study, we have identified 3 compounds, 
JH1, JH4, and JH13, that efficiently block progerin–lamin A/C 
early cysts in LmnaG609G/G609G mice was recovered following JH4 
treatment and returned to numbers similar to those detected in 
WT mice (Supplemental Figure 12I). To examine the effect of JH4 
at the molecular level, we measured the expression of progerin as 
well as array-target genes such as Rad51 and cell-cycle regulators. 
Consistent with our microarray data described above, the expres-
sion level of these genes was restored by JH4 treatment in an injec-
tion time–dependent manner (Figure 7J, Supplemental Figure 13, 
A8 and B8). Moreover, progerin expression was reduced to unde-
tectable levels (Figure 7J).
Specific effect of JH4 on progerin-expressing mice. Because 
Lmna+/G609G progerin heterozygous mice also exhibit progeroid 
features, we checked the effect of JH4 on these animals and found 
that injection of JH4 (twice/week) over a 20-week period  also 
ameliorated a number of aging phenotypes present in these mice, 
such as loss of BW (Figure 8, A and B, and Supplemental Figure 
14A) and dermal and heart muscle alterations (Supplemental Fig-
ure 14B). Moreover, treatment of Lmna+/G609G mice with JH4 could 
result in recovery of their BW to that of normal mice (Figure 8B). 
To investigate whether the in vivo antiprogeria effects of JH4 are 
due to the inhibition of progerin–lamin A binding or to an unknown 
side effect of this compound, we decided to test JH4 in a proger-
in-independent progeria model, namely the zinc metallopeptidase 
STE24-deficient mouse (Zmpste24–/–) (38), in which the progeroid 
phenotype is caused by prelamin A rather than by progerin accu-
mulation. Despite the nearly identical progeroid phenotype of 
Zmpste24–/– and LmnaG609G/G609G mice, JH4 did not produce any 
noticeable change of growth in Zmpste24–/– mice (Supplemental 
Figure 14C), demonstrating that the antiaccelerated aging activ-
ity of JH4 is directly related to its inhibition of progerin’s delete-
rious effects. Indeed, the interaction between progerin and lamin 
A/C in tissues was disrupted by a single JH4 injection (Figure 8C), 
following its metabolic tract. Disruption of progerin–lamin A/C 
binding by JH4 in liver at 6 hours was observed after 24 hours in 
kidney. We were able to recover the progerin-binding biotin-JH4 
(labeled “07” in Figure 8D) in liver 6 hours after injection, indi-
cating, as we expected, that JH4 could work in an in vivo system.
JH4 extends lifespan in the progerin mouse model. Next, we 
assessed the lifespan of LmnaG609G/G609G progeroid mice after JH4 
Figure 8. Lifespan extension in progerin-expressed mice. (A) Represen-
tative photograph of 40-week-old Lmna+/G609G control or JH4-treated mice. 
(B) BW of 40-week-old Lmna+/G609G control and JH4-treated mice. (C) In vivo 
effect of JH4 on binding between progerin and lamin A/C. Lmna+/G609G mice 
that received a single injection of JH4 (10 mg/kg) were sacrificed for IP 
analysis of liver and kidney. After 6 hours, JH4 could disrupt the interaction 
of progerin and lamin A. After 24 hours, dissociation of progerin and lamin 
A was detected in kidney. Extracted proteins were immunoprecipitated 
with progerin Ab, and the precipitated proteins were subjected to Western 
blotting with anti–lamin A/C or anti-progerin Ab. (D) Detection of JH4 in 
liver. Biotin-JH4 was injected into Lmna+/G609G mice, and liver lysates were 
reacted with streptavidin beads. Precipitated proteins were analyzed by 
Western blotting. (E) Kaplan-Meier survival plots for LmnaG609G/G609G mice 
treated with JH4 (n = 13) or with vehicle alone (n = 11). (F) Kaplan-Meier sur-
vival plots for Lmna+/G609G mice treated with vehicle (n = 6) or JH4 (n = 10). 
(G) Extension of lifespan by high-dose injection of JH4. A dose of 20 mg/
kg JH4 could extend lifespan by as much as 26 weeks. (B and E–G) P values 
were determined by Student’s t test.
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recombinant proteins were purified using a nickel column. For the 
binding assay, GST-bead-lamin A/C or progerin-C was incubated 
with lysate from 293 cells that had been transfected with recombi-
nant lamin A N-terminal region, lamin A middle region, GFP–lamin 
A, lamin B or lamin C for 2 hours at room temperature. After washing 
twice with PBS and once with RIPA buffer (50 mM Tris, 150 mM NaCl, 
1% NP-40, 0.5% deoxycholate, and 0.5% SDS), precipitated materials 
were collected and subjected to SDS-PAGE and Western blotting using 
anti-GFP, His, and GST Abs.
Streptavidin-biotin–binding assay. Biotin-conjugated JH4 was pro-
duced by chemical synthesis (see the Chemical Synthesis section in 
the Supplemental materials). To determine the location of JH4-biotin, 
cells were incubated with biotin or biotin-JH4 for the indicated dura-
tions (Figure 3) and fixed with 2% PFA. After permeabilization, block-
ing with BSA, and prereaction with H2O2 to eliminate endogenous 
HRP activity, cells were incubated with streptavidin-HRP (Sigma- 
Aldrich) and DAB solution (Vector Laboratories). To investigate the 
direct binding of JH4 and progerin, cells lysates, precleared by strepta-
vidin-bead, were incubated with biotin-JH4 or biotin and streptavi-
din-bead, sequentially. The precipitated materials were subjected to 
SDS-PAGE and Western blot analysis.
Microarray data. The full data set is available in the NCBI’s Gene 
Expression Omnibus (GEO) database (GEO GSE84147; www.ncbi.
nlm.gov/geo/query/acc.cgi?acc=GSE84147).
Statistics. All data are expressed as the mean ± SEM. Statistical sig-
nificance was determined using a 2-tailed Student’s t test. For all experi-
ments, a P value of less than 0.05 was considered statistically significant.
Study approval. All in vivo studies were performed at an Associ-
ation for Assessment and Accreditation of Laboratory Animal Care–
certified facility, in compliance with animal policies approved by 
Pusan National University (Busan, Korea) and the Universidad de 
Oviedo (Asturias, Oveido, Spain).
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binding and reverse or alleviate different senescence features 
characteristic of HGPS cells, including growth arrest, SA–β-gal 
accumulation, and nuclear aberrations. Moreover, we observed 
similarly favorable effects of JH chemicals on normal aged fibro-
blasts, which also express progerin. Indeed, JH4 suppressed 
SA–β-gal activity and increased the proliferation of these cells. 
Moreover, many genes altered by JH4 treatment were common 
between HGPS and aging cells. The fact that this compound also 
rescued several progeroid features of LmnaG609G/G609G mice and 
extended the lifespan of this HGPS mouse model represents a 
proof of principle for the in vivo relevance of blocking proger-
in–lamin A/C interaction as a new treatment strategy for HGPS 
and, eventually, for age-associated alterations involving nuclear 
envelope abnormalities.
Methods
Animal experiments. Progerin-heterozygous Lmna+/G609G mice were pro-
vided by Carlos López-Otín (Universidad de Oviedo, Asturias, Ovie-
do, Spain). Timed matings of heterozygous Lmna+/G609G and homozy-
gous LmnaG609G/G609G males and females were conducted, and chemical 
was  intraperitoneally injected for indicated weeks or months (Figure 
8, E–G). All mice were maintained on outbred C57BL6/J backgrounds.
Histology. Following sacrifice at the end of the injection regimen, 
the indicated organs (foot pad, kidney, and heart) were isolated in PBS 
and fixed in 10% formaldehyde in PBS at 4°C for 6 to 12 hours. Tissue 
was dehydrated using ethanol (50%, 70%, 90%, 3 × 100%; 5 minutes 
each) and paraffin embedded for sectioning. Sections (5-μm-thick) 
were used for H&E staining.
Chemical screening and chemical synthesis. For chemical screening, 
an ELISA was established by modifying a previously described plat-
form (44). Details on the synthetic methods used are provided in the 
Supplemental material.
Cell culture and reagents. Human fibroblast cells were obtained 
from the Coriell Cell Repositories. Human cancer cell lines (HCT116, 
A549, and HEK293), obtained from ATCC, were maintained in liquid 
medium containing 10% FBS and 1% antibiotics at 37°C. Nonhuman 
cell lines such as Vero (monkey), HICIC7 (mouse), MDCK (canine), 
and Mv1Lu (mink) were obtained from the Korean Cell Line Bank 
(KCLB, Seoul, Korea).
Plasmids and transfection. GFP-progerin and GFP-fused lamin 
A expression vectors were provided by T. Misteli (National Cancer 
Institute [NCI], Bethesda, Maryland, USA). GFP-lamin B1 and lamin 
C were provided by J. Lammerding (Brigham and Women’s Hospital/
Harvard Medical School, Boston, Massachusetts, USA). Mutant forms 
of lamin A were gifts of F. Tesson (University of Ottawa, Ottawa, 
Ontario, Canada). The Myc-ARF vector and OST-LAMINA Δ50 vec-
tor were purchased from Addgene. Transfection was performed using 
jetPEI (Polyplus Transfection) following the manufacturer’s protocol.
Recombinant proteins and GST pull-down assay. For investigation 
of protein-protein interactions, recombinant proteins were generated. 
Recombinant lamin A N-terminal region (His-LMNA-N; aa residues 
1-300) and middle region (His-LMNA-M; 301-564 aa) was cloned into 
His-tagged pPROEXHT. GST-fused recombinant lamin A-C terminal 
region (GST-LMNA) and progerin C-terminal region (GST-progerin) 
were produced by PCR cloning 100 aa upstream of the termination 
codon through PCR. Full-length p14ARF was produced by PCR, cloned 
into the pGEX vector, and confirmed by DNA sequencing. These 
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